Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

46.69USD
5 Dec 2016
Change (% chg)

$0.43 (+0.93%)
Prev Close
$46.26
Open
$46.20
Day's High
$46.69
Day's Low
$46.05
Volume
41,102
Avg. Vol
56,775
52-wk High
$54.70
52-wk Low
$40.74

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters
Tuesday, 25 Oct 2016 09:33am EDT 

Dr.Reddy's Laboratories Ltd : Exec says have addressed all FDA requirements on warning letters . Exec says pricing erosion has become a part of U.S. business model Further company coverage: [REDY.NS] (Bengaluru newsroom) ((ReutersIndia.snapping@thomsonreuters.com ;)).  Full Article

Dr.Reddy's Labs announces entry into Columbia
Friday, 7 Oct 2016 09:11am EDT 

Dr.Reddy's Laboratories Ltd :Announces entry into Columbia.  Full Article

DR. Reddy's laboratories says launch of Bupropion HCL extended-release tablets, USP (sr) in U.S. market
Friday, 2 Sep 2016 11:32am EDT 

Dr.Reddy's Laboratories Ltd :Launch of bupropion hcl extended-release tablets, usp (sr) in u.s. Market.  Full Article

Dr.Reddy's Laboratories says June-qtr consol net profit falls about 76.2 pct
Tuesday, 26 Jul 2016 05:12am EDT 

Dr.Reddy's Laboratories Ltd : June -quarter pat 4.09 billion rupees - tv . June -quarter consol net profit 1.54 billion rupees; consol net sales inr 31.64 billion . Consensus forecast for June-quarter profit was 4.95 billion rupees . Consol net profit in June-quarter last year was 6.47 billion rupees as per Ind-AS; consol net sales was 37.01 billion rupees . In quarter, top and bottom lines impacted by fall in volume growth, mainly in U.S. markets, loss of business in Venezuela . Co faced challenges in quarter including price erosion and delayed launches due to warning letter, which significantly impacted earnings .  Full Article

Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier
Tuesday, 31 May 2016 07:02am EDT 

Spectrum Pharmaceuticals : Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn .dr. Reddy's will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain circumstances.  Full Article

Dr. Reddy's Labs acquires six OTC brands from Ducere Pharma
Wednesday, 25 May 2016 05:27am EDT 

Dr.Reddy's Laboratories Ltd : Dr. Reddy's enters the branded consumer health arena through the acquisition of six OTC brands . Co acquired six OTC brands from Ducere Pharma .  Full Article

Dr.Reddy's expects more launches in North America in fiscal 2017
Thursday, 12 May 2016 07:31am EDT 

Dr.Reddy's Laboratories Ltd : COO mukherjee says spent 136 crore rupees in Q4 on remediation of plants under November warning letter . COO says expect more product launches in North America in fiscal 2017 versus a year earlier . Labs COO says to send final update to FDA on warning letter by may with nearly 90 percent of issues resolved . Further company coverage [REDY.NS] ((Bengaluru Newsroom; +91 80 6749 1130)).  Full Article

Dr.Reddy's Laboratories March-qtr consol profit falls
Thursday, 12 May 2016 03:47am EDT 

Dr.Reddy's Laboratories Ltd : March-quarter consol net profit 746 million rupees; March-quarter consol net income from sales and services 37.56 billion rupees . Not got approval from venezuelan government to repatriate amount beyound $4 million recieved during the year . Current outstanding recievable from venezeulan unit up to 3.56 billion rupees presented as exceptional item . recommended final dividend of INR 20 per share .  Full Article

Dr.Reddy's Laboratories Ltd calls out for Paricalcitol capsules lot from US - ASNEWS
Friday, 26 Feb 2016 09:15pm EST 

Dr.Reddy's Laboratories Ltd:Dr Reddy's Laboratories has started recalling some lots of its Paricalcitol Capsules of one mcg, two mcg four mcg strengths from the US markets. - ASNEWS.The company called for actions voluntarily due to reports of breakage and leakage of the capsules.According to a notification put by the US Food and Drug Administration, these lots are recalled under 'Class-III' classification, which was described as a situation in which use of or exposure to a violated product is not likely to cause adverse health consequences.Paricalcitol, a Vitamin-D compound is used for preventing and treating high levels of parathyroid hormone in certain patients.The firm is recalling 24,661 bottles from the market from November last year. These capsules are manufactured at DRL's Bachupally unit in Hyderabad.  Full Article

Dr.Reddy's Laboratories Ltd's Promius Pharma receives FDA Approval for Sernivo (betamethasone dipropionate) Spray, 0.05%
Sunday, 7 Feb 2016 10:37pm EST 

Dr.Reddy's Laboratories Ltd:Says that its US subsidiary, Promius PharmaTM, LLC, U.S, has received approval for Sernivo (betamethasone dipropionate) Spray, 0.05% from U.S. Food and Drug Administration (FDA).Say sSernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.Says commercial launch of the product is planned for the coming quarter.  Full Article

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage: